4.7 Article

Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis

Journal

ANNALS OF THE RHEUMATIC DISEASES
Volume 75, Issue 9, Pages 1599-1606

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2015-207762

Keywords

Autoimmune Diseases; Dermatomyositis; Epidemiology; Gene Polymorphism; Disease Activity

Categories

Funding

  1. National Institute of Arthritis, Musculoskeletal and Skin Diseases, the National Institutes of Health [5R01 AR054459]
  2. CureJM Foundation
  3. Research Institute of the Nationwide Children's Hospital
  4. National Institute of Environmental Health Sciences, National Institutes of Health

Ask authors/readers for more resources

Objective Complement-mediated vasculopathy of muscle and skin are clinical features of juvenile dermatomyositis (JDM). We assess gene copy-number variations (CNVs) for complement C4 and its isotypes, C4A and C4B, in genetic risks and pathogenesis of JDM. Methods The study population included 105 patients with JDM and 500 healthy European Americans. Gene copy-numbers (GCNs) for total C4, C4A, C4B and HLA-DRB1 genotypes were determined by Southern blots and qPCRs. Processed activation product C4d bound to erythrocytes (E-C4d) was measured by flow cytometry. Global gene-expression microarrays were performed in 19 patients with JDM and seven controls using PAXgene-blood RNA. Differential expression levels for selected genes were validated by qPCR. Results Significantly lower GCNs and differences in distribution of GCN groups for total C4 and C4A were observed in JDM versus controls. Lower GCN of C4A in JDM remained among HLA DR3-positive subjects (p=0.015). Homozygous or heterozygous C4A-deficiency was present in 40.0% of patients with JDM compared with 18.2% of controls (OR=3.00 (1.87 to 4.79), p=8.2x10(-6)). Patients with JDM had higher levels of E-C4d than controls (p=0.004). In JDM, C4A-deficient subjects had higher levels of E-C4d (p=0.0003) and higher frequency of elevated levels of multiple serum muscle enzymes at diagnosis (p=0.0025). Microarray profiling of blood RNA revealed upregulation of type I interferon-stimulated genes and lower abundance of transcripts for T-cell and chemokine function genes in JDM, but this was less prominent among C4A-deficient or DR3-positive patients. Conclusions Complement C4A deficiency appears to be an important factor for the genetic risk and pathogenesis of JDM, particularly in patients with a DR3-positive background.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Rheumatology

Response to: 'Correspondence on 'EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups'' by Irfan et al

Ingrid E. Lundberg, Frederick W. Miller, Lisa G. Rider, Victoria P. Werth, Anna Tjarnlund, Matteo Bottai

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Clinical Neurology

Cerebral organoids containing an AUTS2 missense variant model microcephaly

Summer R. Fair, Wesley Schwind, Dominic Julian, Alecia Biel, Gongbo Guo, Ryan Rutherford, Swetha Ramadesikan, Jesse Westfall, Katherine E. Miller, Meisam Naeimi Kararoudi, Scott E. Hickey, Theresa Mihalic Mosher, Kim L. McBride, Reid Neinast, James Fitch, Dean Lee, Peter White, Richard K. Wilson, Tracy A. Bedrosian, Daniel C. Koboldt, Mark E. Hester

Summary: Variants in the AUTS2 gene are associated with a broad spectrum of neurological conditions. In this study, a human cerebral organoid model was used to investigate the pathophysiology of a specific variant. The study found that the variant led to reduced growth and disrupted cell proliferation in the organoids. Gene editing was able to correct the variant and restore organoid growth and cell proliferative capacity. Single-cell RNA sequencing revealed changes in gene expression and signaling pathways. These findings highlight the importance of cerebral organoids in studying the molecular mechanisms underlying AUTS2 syndrome.

BRAIN (2023)

Article Oncology

Infantile metastatic ependymoma with a novel molecular profile and favorable outcome to intensive chemotherapy without irradiation: Case-based review

Flavia Watusi De Faria, Kathleen M. Schieffer, Christopher R. Pierson, Daniel R. Boue, Stephanie LaHaye, Katherine E. Miller, Nisreen Amayiri, Daniel C. Koboldt, Tara Lichtenberg, Kristen Leraas, Patrick Brennan, Ben Kelly, Peter White, Vincent Magrini, Richard K. Wilson, Elaine R. Mardis, Catherine E. Cottrell, Jerome Rusin, Jonathan L. Finlay, Diana S. Osorio

Summary: Ependymal tumors are the third most common brain tumor in children under 14 years old, and metastatic disease, although rare, has a negative prognosis especially in young children. Limited data is available on how to manage metastatic disease in patients under 3 years old. This study provides a literature review on clinical characteristics and radiation-sparing treatments for metastatic ependymoma in children under 3 years old. Chemotherapy-based approaches were used with radiation reserved for progression or relapse, and the overall survival rate varied among studies.

GENES CHROMOSOMES & CANCER (2023)

Letter Pediatrics

The post-diagnostics world: charting a path for pediatric genomic medicine in the twenty-first century

Joshua L. Bonkowsky, Tomi Pastinen, Peter White

PEDIATRIC RESEARCH (2023)

Article Rheumatology

Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features

Matthew A. Sherman, Rose Graf, Sara E. Sabbagh, Angeles S. Galindo-Feria, Iago Pinal-Fernandez, Katherine Pak, Takayuki Kishi, Willy A. Flegel, Ira N. Targoff, Frederick W. Miller, Ingrid E. Lundberg, Lisa G. Rider, Andrew L. Mammen

Summary: This study found the presence of anti-FHL1 autoantibodies in juvenile IIM patients, which were associated with MAAs and specific skin rash, but not with other clinical features or worse outcomes.

RHEUMATOLOGY (2023)

Letter Critical Care Medicine

Human Leukocyte Antigen Alleles Associated with Interstitial Lung Disease in North Americans with Idiopathic Inflammatory Myopathy

Cheilonda Johnson, Adam I. Schiffenbauer, Frederick W. Miller, Jamie Perin, Sonye K. Danoff, Avantika R. Diwadkar, Jaehyun Joo, Blanca E. Himes, Nuala J. Meyer

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2023)

Article Rheumatology

Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies

Danlei Zhou, Emily H. King, Simon Rothwell, Olga Krystufkova, Antonella Notarnicola, Samantha Coss, Rabheh Abdul-Aziz, Katherine E. Miller, Amanda Dang, G. Richard Yu, Joanne Drew, Emeli Lundstrom, Lauren M. Pachman, Gulnara Mamyrova, Rodolfo Curiel, Boel De Paepe, Jan L. De Bleecker, Antony Payton, William Ollier, Terrance P. O'Hanlon, Ira N. Targoff, Willy A. Flegel, Vidya Sivaraman, Edward Oberle, Shoghik Akoghlanian, Kyla Driest, Charles H. Spencer, Yee Ling Wu, Haikady N. Nagaraja, Stacy P. Ardoin, Hector Chinoy, Lisa G. Rider, Frederick W. Miller, Ingrid E. Lundberg, Leonid Padyukov, Jiri Vencovsky, Janine A. Lamb, Chack-Yung Yu

Summary: C4A deficiency is relevant in dermatomyositis, HLA-DRB1*03 is important in IBM, and both C4A deficiency and HLA-DRB1*03 contribute interactively to the risk of polymyositis.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Urine proteomics by mass spectrometry identifies proteins involved in key pathogenic pathways in patients with juvenile dermatomyositis

Melissa Morales, Tchilabalo D. Alayi, Shefa M. Tawalbeh, Agnes Sydenstricker, Rita Spathis, Hanna Kim, Kanneboyina Nagaraju, Yetrib Hathout, Lisa G. Rider

Summary: This study aimed to identify and validate biomarkers in children with juvenile dermatomyositis (JDM) using a multiplexing tandem mass tag urine proteome profiling approach. The results confirmed the presence of elevated cathepsin D and galectin-3 binding protein in the urine of JDM patients, supporting previous findings in myositis patients. The study also identified novel candidate biomarkers related to myositis.

RHEUMATOLOGY (2023)

Article Rheumatology

Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy

Rodolfo Curiel, William Nguyen, Gulnara Mamyrova, Derek Jones, Alison A. Ehrlich, Kathleen Brindle, Shahriar Haji-Momenian, Robert Sheets, Hanna Y. Kim, Olcay G. Jones, Lisa Rider

Summary: This 24-week open-label study aimed to evaluate the safety and efficacy of abatacept in patients with refractory juvenile dermatomyositis (DM). Ten patients with moderate disease activity were enrolled to examine the safety of subcutaneous abatacept and patient responses. The results showed improvements in disease activity, decrease in glucocorticoid doses, and decrease in muscle edema.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Identification of Novel Associations and Localization of Signals in Idiopathic Inflammatory Myopathies Using Genome-Wide Imputation

Simon I. Rothwell, Christopher W. Amos, Frederick G. Miller, Lisa E. Rider, Ingrid K. Lundberg, Peter Gregersen, Jiri Vencovsky, Neil McHugh, Vidya Limaye, Albert G. Selva-O'Callaghan, Michael M. Hanna, Pedro M. Machado, Lauren M. Pachman, Ann Reed, Oyvind Molberg, Olivier Benveniste, Pernille Mathiesen, Timothy Radstake, Andrea L. Doria, Jan De Bleecker, Boel De Paepe, Britta E. Maurer, William Ollier, Leonid P. Padyukov, Terrance O'Hanlon, Annette R. Lee, Lucy Wedderburn, Hector A. Chinoy, Janine Lamb

Summary: In this study, genetic analysis of samples from patients with idiopathic inflammatory myopathies (IIMs) identified novel gene variants and localized signals to specific immune cell types. These findings provide new insights into the pathogenesis of IIMs.

ARTHRITIS & RHEUMATOLOGY (2023)

Article Rheumatology

Development of a computed tomography calcium scoring technique for assessing calcinosis distribution, pattern and burden in dermatomyositis

Briana A. Cervantes, Prateek Gowda, Lisa G. Rider, Frederick W. Miller, Marcus Y. Chen, Adam Schiffenbauer

Summary: This study used whole-body CT scans and calcium scoring techniques to assess calcinosis in patients with adult and juvenile dermatomyositis. Different patterns and new locations of calcinosis were observed using CT scans and the Agatston scoring method, which can effectively evaluate and track calcinosis in these patients.

RHEUMATOLOGY (2023)

Article Rheumatology

Association of anti-TPM4 autoantibodies with vasculopathic cutaneous manifestations in juvenile dermatomyositis

Rie Karasawa, Kazuo Yudoh, Toshiko Sato, Megumi Tanaka, Sara E. Sabbagh, Willy A. Flegel, Andrew L. Mammen, James N. Jarvis, Lisa G. Rider

Summary: By using Western blotting, the expression of TPM4 protein in normal human dermal microvascular ECs was investigated. Using ELISA, anti-TPM4 autoantibodies were detected in 30% of JDM plasma samples. These autoantibodies were associated with certain clinical features of JDM, such as cutaneous ulcers, shawl sign rash, mucous membrane lesions, and subcutaneous edema.

RHEUMATOLOGY (2023)

Article Rheumatology

Performance of the 2016 ACR-EULAR Myositis Response Criteria in adult dermatomyositis/polymyositis therapeutic trials and consensus profiles

Didem Saygin, Hanna Kim, Christian Douglas, Brian Erman, Jesse Wilkerson, John A. McGrath, Chester Oddis, Ingrid E. Lundberg, Anthony A. Amato, Ignacio Garcia-De La Torre, Hector Chinoy, David Fiorentino, Lorinda Chung, Yeong-Wook Song, Frederick W. Miller, Nicolino Ruperto, Jiri Vencovsky, Rohit Aggarwal, Lisa G. Rider

Summary: This study further validated the ACR-EULAR Myositis Response Criteria (MRC) by assessing the contribution of each core set measure, the frequency of improvement in strength vs extramuscular activity, the representation of patient-reported outcome measures (PROM), and the frequency of core set measure worsening. The results showed that improvement in strength was the main contributing factor, and the majority of patients also had improvement in PROM.

RHEUMATOLOGY (2023)

Article Rheumatology

Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles

Hanna Kim, Didem Saygin, Christian Douglas, Jesse Wilkerson, Brian Erman, Angela Pistorio, John A. McGrath, Ann M. Reed, Chester Oddis, Claudia Bracaglia, Annet van Royen-Kerkhof, Blanca Bica, Pavla Dolezalova, Virginia P. L. Ferriani, Berit Flato, Ana G. Bernard-Medina, Troels Herlin, Frederick W. Miller, Jiri Vencovsky, Nicolino Ruperto, Rohit Aggarwal, Lisa G. Rider

Summary: The 2016 ACR-EULAR response criteria for JDM is a composite measure with six core set measures to calculate a total improvement score. This study evaluated the contribution of each measure, representation of muscle-related and patient-reported measures, and frequency of measure worsening across improvement categories. The results support the consistent performance of the ACR-EULAR MRC across multiple studies and its further use as an efficacy endpoint in JDM trials.

RHEUMATOLOGY (2023)

Article Rheumatology

Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial Design

Laura E. Schanberg, Lily (Yeruk) Mulugeta, Bolanle Akinlade, Hermine I. Brunner, Jianmeng Chen, Robert A. Colbert, Vincent Delgaizo, Marc R. Gastonguay, Rachel Glaser, Lisa Imundo, Daniel J. Lovell, Jocelyn H. Leu, Nael M. Mostafa, Robert M. Nelson, Peter A. Nigrovic, Nikolay P. Nikolov, Lisa G. Rider, Rebecca Rothwell, Chandrahas Sahajwalla, Renu Singh, Vikram Sinha, Carolyn L. Yancey, Lynne Yao

Summary: This report summarizes a workshop on drug development for polyarticular juvenile idiopathic arthritis (pJIA), highlighting the importance of accelerating drug development and the necessity of collaboration between stakeholders.

ARTHRITIS & RHEUMATOLOGY (2023)

No Data Available